major depressive disorder
Conditions
Interventions
Escitalopram
Paroxetine-CR
Sponsors
Department of Psychiatry, Fujita Health University School of Medicine
The Okehazama Hospital The Jindai Hospital The St. Cross Hospital The Toyota Memorial Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients (inpatients and outpatients), diagnosed with major depressive disorder (according to the DSM-IV-TR criteria) Patients with HAM-D17 total score 20 or more
Exclusion criteria
Exclusion criteria: Patient with the following disorders (based on DSM-IV-TR criteria): psychotic disorders, pervasive developmental disorders, bipolar disorder, obsessive-compulsive disorder, Axis-2 disorder. Patients with substance abuse or dependence (excluding nicotine and caffeine) meeting DSM-IV-TR criteria Patients taking MAO inhibitors with in14 days (or Patients treated with MAO inhibitors within 14 days) Patients taking pimozide Patients with allergies to escitalopram, citalopram and paroxetine Patients with QT interval prolongation Patients treated with ECT within the previous 6 months Patients having severe physical disease Patients who are pregnant or may become pregnant Patients at significant risk of suicide (having a score >3 on HAM-D item 11) Patients who had made suicide attempt within the past year
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Hamilton Rating Scale for Depression | — |
Secondary
| Measure | Time frame |
|---|---|
| Remission rate | — |
Countries
Japan
Contacts
Public ContactTaro Kishi
Fujita Health University School of Medicine Department of Psychiatry
Outcome results
None listed